This GLP-1 antagonist is useful for dissecting endogenous GLP-1 responses and validating GLP-1 receptor-dependent effects

I numeri da tenere a mente Riduzione MACE (eventi cardiovascolari maggiori) Semaglutide vs placebo : 26% nel diabete con alto rischio CV (SUSTAIN-6) 20% nellobesit con malattia CV (SELECT) 14% con la formulazione orale (SOUL) Tirzepatide vs dulaglutide : 12,2% vs 13,1% MACE-3 a 4 anni (non inferiorit raggiunta, p=0,003) Mortalit totale Semaglutide : dati positivi in FLOW (20%) e SOUL Tirzepatide : 16% rispetto a dulaglutide (SURPASS-CVOT) Perdita di peso a 72 settimane (dose massima) Semaglutide 2,4 mg : 14,9% (STEP-1, senza diabete) 9,6% (STEP-2, con diabete) Tirzepatide 15 mg : 22,5% (SURMOUNT-1, senza diabete) 15,7% (SURMOUNT-2, con diabete) Steatoepatite (MASH F2-F3, 72 settimane) Semaglutide 2,4 mg (ESSENCE): risoluzione MASH 62,9% vs 34,1% placebo Tirzepatide 10-15 mg (SYNERGY-NASH): risoluzione MASH 51-62% vs 10% placebo Domande frequenti (FAQ) Qual la differenza tra Ozempic, Wegovy, Rybelsus e Mounjaro

For instance, the variability in insulin absorption was reported as 15~25% for the same patient, and as 20~45% among patients 11
June 13, 2024
Advancements in drug formulations, synergistic combinations with other antidiabetic medications, and improved safety profiles are poised to drive market expansion during the forecast period
10.1152/physrev.00034.2006 11